(Q33930605)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

main subject

dasatinib monohydrate

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Kimmo Porkka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Satu Mustjoki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Mette Ilander

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Jukka Vakkila

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

29 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

e28925

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

Immunology and immunotherapy of chronic myeloid leukemia

11 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Cutting Edge: Responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Clinical pharmacokinetics of tyrosine kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Phenotype and function of human T lymphocyte subsets: consensus and issues

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Primary antitumor immune response mediated by CD4+ T cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

The molecular biology of chronic myeloid leukemia.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4106168

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

5 July 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Dasatinib suppresses in vitro natural killer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.28925

Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib

21 January 2018

1 reference

12 December 2020

Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro

1 reference

12 December 2020

Anticancer effects of imatinib via immunostimulation

1 reference

12 December 2020

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

12 December 2020

Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood

1 reference

12 December 2020

Identifiers

DOI

10.4161/ONCI.28925

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

release_pj54zok45zbnhme5zneorpzthq

11 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pj54zok45zbnhme5zneorpzthq

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

PubMed publication ID

25083322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25083322%20AND%20SRC:MED&resulttype=core&format=json